Rick Doubleday is the executive vice president, and chief commercial officer at Dexcom. He is responsible for the sales, marketing and customer service functions. Previously, Doubleday led all sales and marketing functions for the company, driving the acceleration of worldwide awareness and adoption of Dexcom continuous glucose monitoring (CGM). Doubleday visited The American Journal of Managed Care® this fall to discuss bringing the Dexcom G5 to Medicare beneficiaries.
Rick Doubleday is the executive vice president, and chief commercial officer at Dexcom. He is responsible for the sales, marketing and customer service functions. Previously, Doubleday led all sales and marketing functions for the company, driving the acceleration of worldwide awareness and adoption of Dexcom continuous glucose monitoring (CGM). Doubleday visited The American Journal of Managed Care® to discuss bringing the Dexcom G5 to Medicare beneficiaries.
Transcript
Can you describe how Medicare beneficiaries have responded to the news about reimbursement for the Dexcom G5? What steps has Dexcom taken to respond to demand?
Medicare beneficiaries are thrilled that the Dexcom G5 is now being reimbursed [to] those beneficiaries that have diabetes. We are the first one to get a class for Medicare beneficiaries to actually get continuous glucose monitoring. Continuous glucose monitoring is a tool that individuals with diabetes using insulin can actually get continuous glucose readings which helps them better manage their disease. It has alerts and alarms which will alert them when they are going either high or low, so these beneficiaries who frequently suffer from hypoglycemia, hypo-unaware, are thrilled that they now have access to this technology.
How is the Medicare reimbursement process going and how has Dexcom set itself up to respond to demand?
Medicare reimbursement is going well, one thing that everyone has to remember is that we are about 18 months ahead of when we expected to get the reimbursement and so, we’re playing catch-up. We would all like the beneficiaries to be getting these devices faster than they are, but we have ramped a team to be able to support them and we are continuously growing the number of patients that are getting the device.
Will Medicare revisit the decision to not allow beneficiaries to use CGM with their smartphone? What is Dexcom doing to facilitate this?
Dexcom is always the first to the market, and we’re the first to actually get the Medicare reimbursement. And we’re thrilled that CMS made a decision to cover continuous glucose monitoring. As part of that ruling, we’re classified as a Medicare part B, which is a durable medical equipment. Part of that is you have to use the durable device, which is the receiver, and we are getting the benefit to patients. We are actively working with CMS to try and open up access to the smartphone. We believe that it’s very important for these beneficiaries to have the ability to use their smartphones. We will continue to work on this and when there’s more information we will absolutely share it with these beneficiaries.
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Prices for care at hospital trauma centers vary across hospitals; drug shortages reached a record high during the first quarter of 2024; although 3 of the biggest makers of asthma inhalers pledged to cap out-of-pocket costs for some US patients at $35, these do not apply to daily inhalers used by the youngest kids with asthma.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
The Biden administration recently launched the Global Health Security Strategy, a new effort to combat the spread of infectious diseases; lawmakers zeroed in on the risks of massive consolidation in health care during the first congressional hearing on the Change Healthcare hack; the FDA recently announced the recall of a pair of heart devices linked to numerous deaths and injuries.
Read More